Biofrontera Inc.
BFRI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BFRI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BFRI
Biofrontera Inc. is a commercial-stage biopharmaceutical company focused on dermatological therapies, primarily marketing Ameluz (aminolevulinic acid) with the RhodoLED lamp for actinic keratosis, while facing significant financial challenges and a going-concern risk.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$23.6M
Cash Runway
12.9 moLead Asset
ameluz (Phase 3)Next Catalyst
Patent_Expiry · Dec 8, 2043Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials · 1 catalyst · 1 FDA decision for Biofrontera Inc..
Biofrontera Inc. is a commercial-stage biopharmaceutical company focused on dermatological therapies, primarily marketing Ameluz (aminolevulinic acid) with the RhodoLED lamp for actinic keratosis, while facing significant financial challenges and a going-concern risk.
- Primary product is Ameluz in combination with RhodoLED lamps for minimally to moderately thick actinic keratoses of the face and scalp [sec_mda · as of 2026-03-19].
- Cash and cash equivalents were $4.9 million as of 2026-06-30 [sec].
- Total revenue was $12.0 million for the trailing twelve months as of 2026-06-30 [sec].
- Net loss was $0.6 million for the same period [sec].
- Management has expressed substantial doubt about the company's ability to continue as a going concern for twelve months from the date of its Annual Report [sec_mda · as of 2026-03-19].
What works
- Adjusted EBITDA improved from ($15.3) million in 2024 to ($10.6) million in 2025, reflecting higher gross profit and disciplined cost management [sec_mda · as of 2026-03-19].
- The company took control of all U.S. clinical trials for Ameluz in June 2024, allowing more direct oversight and cost management [sec_mda · as of 2025-03-20].
- Strategy focuses on expanding U.S. sales of Ameluz and positioning it as a standard of care for actinic keratosis [sec_mda · as of 2026-03-19].
What to weigh
- As of December 31, 2025, cash and cash equivalents were only $6.4 million, and management believes capital is not adequate for twelve months of operations [sec_mda · as of 2026-03-19].
- The company has a history of operating losses and anticipates continued losses [sec · filed 2025-12-05].
- Substantial doubt exists about the company's ability to continue as a going concern [sec_mda · as of 2026-03-19].
- The company faces significant competition from other pharmaceutical and medical device companies, as well as established treatments like cryotherapy [sec · filed 2025-12-05].
From the filings
Quoted directly from source documents.
Going concern risk
“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the date of this Annual Report on Form 10-K.”
SEC MD&A · March 19, 2026
Cash position as of Dec 31, 2025
“As of December 31, 2025, we had cash and cash equivalents of $6.4 million.”
SEC MD&A · March 19, 2026
Primary strategy
“expanding our sales in the United States of Ameluz in combination with the RhodoLED Lamps for the treatment of minimally to moderately thick AKs of the face and scalp and positioning Ameluz to be the standard of care in the United States”
SEC MD&A · March 19, 2026
Competition risk
“We face significant competition from other pharmaceutical and medical device companies and our operating results will suffer if we fail to compete effectively.”
SEC filings · December 5, 2025
Catalyst timeline
- 2043-12-08 · Patent_Expiry · AMELUZ — Patent/Exclusivity Expiry: AMELUZ — The patent protecting Ameluz is set to expire, which could open the door for generic competition.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has substantial doubt about the company's ability to continue for twelve months from the Annual Report date [sec_mda · as of 2026-03-19].
- Limited cash runway — Cash of $4.9M as of 2026-06-30 may not sustain operations without additional capital [sec].
- History of operating losses — The company has a history of losses and anticipates continued losses [sec · filed 2025-12-05].
- Intense competition — Competition from other drug/device companies and established treatments like cryotherapy [sec · filed 2025-12-05].
What to watch
- Ability to secure additional capital through equity or debt financings or asset sales [sec_mda · as of 2026-03-19].
- Progress in expanding U.S. sales of Ameluz and customer adoption [sec_mda · as of 2026-03-19].
- Outcome of ongoing clinical trials and potential label extensions for Ameluz [sec_mda · as of 2026-03-19].
- Patent expiry for AMELUZ on 2043-12-08 [catalyst].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Biofrontera Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Biofrontera Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.9 months
D/E 3.04 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~6309d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$287K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 109,300 | $88K |
| vanguard capital management llc | 104,508 | $85K |
| vanguard fiduciary trust co | 61,697 | $50K |
| susquehanna international group, llp | 38,574 | $31K |
| xtx topco ltd | 22,493 | $18K |
| citigroup inc | 11,837 | $10K |
| blackrock, inc. | 4,622 | $4K |
| ubs group ag | 1,540 | $1K |
| sbi securities co., ltd. | 305 | $247 |
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 0.6
- Shares short
- 76,357
- Daily short volume (Apr 30, 2026)
- 35.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BFRI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Biofrontera Inc.?
Biofrontera Inc. is a commercial-stage biopharmaceutical company focused on dermatological therapies, primarily marketing Ameluz (aminolevulinic acid) with the RhodoLED lamp for actinic keratosis, while facing significant financial challenges and a going-concern risk.
What is Biofrontera Inc.'s lead drug candidate?
Biofrontera Inc.'s most advanced tracked candidate is ameluz (Phase 3) for Actinic Keratosis (Trunk & extremities).
What is Biofrontera Inc.'s next catalyst?
Biofrontera Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: AMELUZ" — expected December 8, 2043.
Who is the CEO of Biofrontera Inc.?
Dr. Hermann Luebbert Ph.D. is the chief executive officer of Biofrontera Inc. (BFRI).
Where is Biofrontera Inc. headquartered?
Biofrontera Inc. (BFRI) is headquartered in Woburn, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.